Edition:
India

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

1.77EUR
18 Sep 2019
Change (% chg)

-- (--)
Prev Close
€1.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
57,238
52-wk High
€3.30
52-wk Low
€1.65

Latest Key Developments (Source: Significant Developments)

Transgene H1 Operating Revenues Amounted To 4.9 Million Euros
Wednesday, 18 Sep 2019 

Sept 18 (Reuters) - Transgene SA ::TRANSGENE CONFIRMS THE TIMELINE OF ITS CLINICAL NEWS FLOW AND PRESENTS 2019 HALF-YEAR RESULTS.FINANCIAL VISIBILITY UNTIL 2022, FOLLOWING EUR 48.7 MILLION RIGHTS ISSUE.OPERATING REVENUES AMOUNTED TO EUR 4.9 MILLION FOR FIRST SIX MONTHS OF 2019.NET LOSS AMOUNTED TO EUR 15.3 MILLION FOR FIRST HALF OF 2019.AS OF JUNE 30, 2019, COMPANY'S CASH, CASH EQUIVALENTS AND OTHER FINANCIAL ASSETS AMOUNTED TO EUR 12.8 MILLION.CASH BURN AMOUNTED TO EUR 4.1 MILLION IN FIRST HALF OF 2019.  Full Article

Transgene Receives MHRA Approval For TG4050 To Commence Clinical Development
Wednesday, 10 Jul 2019 

July 10 (Reuters) - TRANSGENE SA ::TRANSGENE RECEIVES MHRA APPROVAL FOR LEAD MYVAC™ INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL DEVELOPMENT IN HPV NEGATIVE HEAD AND NECK CANCERS IN THE UK.PHASE 1 CLINICAL TRIAL, EXPECTED TO START IN H2 2019, WILL BE CO-FUNDED BY TRANSGENE AND ITS COLLABORATION PARTNER NEC.PHASE 1 CLINICAL TRIAL OF TG4050 WILL BE CARRIED OUT IN PATIENTS WITH SCCHN THAT HAVE RECEIVED AN ADJUVANT (FIRST LINE) THERAPY.ANTITUMOR ACTIVITY OF TG4050 AS MONOTHERAPY WILL ALSO BE MEASURED.  Full Article

Transgene Raises EUR 48.7 Million Gross In Rights Issue
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Transgene SA ::SUCCESS OF TRANSGENE’S €48.7 MILLION RIGHTS ISSUE.ISSUANCE OF 20,816,366 NEW SHARES AT A SUBSCRIPTION PRICE OF €2.34 PER NEW SHARE.TOTAL NET PROCEEDS OF THE RIGHTS ISSUE ARE EXPECTED TO BE AROUND €47.0 MILLION.  Full Article

Transgene Oncolytic Announces Potential Of TG4001 And TG6002
Wednesday, 5 Jun 2019 

June 5 (Reuters) - TRANSGENE SA ::TRANSGENE: PEER-REVIEWED PUBLICATIONS CONFIRM THE POTENTIAL OF TRANSGENE’S TG4001 AND TG6002.ONCOLYTIC VIRUS TG6002 SHOWS INCREASED TUMOR SELECTIVITY AND STRONG ANTITUMOR ACTIVITY IN SEVERAL PRECLINICAL MODELS.THERAPEUTIC VACCINE TG4001, ADMINISTERED AS A SINGLE AGENT, DEMONSTRATED STATISTICALLY SIGNIFICANT CURATIVE ACTIVITY AT 30 MONTHS IN RANDOMIZED PHASE 2B TRIAL IN HPV-ASSOCIATED CIN 2/3.CLINICAL RESULTS ARE HIGHLY SUPPORTIVE OF ONGOING DEVELOPMENT OF TG4001 IN COMBINATION WITH AVELUMAB IN HPV-POSITIVE CANCERS.TG4001 WAS WELL TOLERATED WITH MOST COMMON ADVERSE EVENTS BEING INJECTION SITE REACTIONS.  Full Article

Transgene Says Results For Primary Endpoint (ORR) Expected In Q4 2019
Monday, 27 May 2019 

May 27 (Reuters) - TRANSGENE SA ::LAST PATIENT ENROLLED IN PHASE 2 TRIAL WITH TRANSGENE'S TG4010.RESULTS FOR THE PRIMARY ENDPOINT (ORR) EXPECTED IN Q4 2019.LAST PATIENT ENROLLED IN PHASE 2 TRIAL WITH TRANSGENE'S TG4010 + NIVOLUMAB + CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED LUNG CANCER (NSCLC).TRIAL HAS ENROLLED PATIENTS WHOSE TUMOR EXPRESSES LOW OR UNDETECTABLE LEVELS OF PD-L1.CLINICAL TRIAL IN COLLABORATION WITH BRISTOL-MYERS SQUIBB.  Full Article

Transgene And Astrazeneca Announce Collaboration For Invir.IO Based Armed Oncolytic Immunotherapies
Thursday, 2 May 2019 

May 2 (Reuters) - TRANSGENE SA ::TRANSGENE AND ASTRAZENECA ENTER INTO A COLLABORATION AND EXCLUSIVE LICENSE OPTION AGREEMENT FOR INNOVATIVE INVIR.IOTM BASED ARMED ONCOLYTIC IMMUNOTHERAPIES.TRANSGENE AND ASTRAZENECA ENTER INTO A COLLABORATION AND EXCLUSIVE LICENSE OPTION AGREEMENT FOR INNOVATIVE INVIR.IOTM BASED ARMED ONCOLYTIC IMMUNOTHERAPIES.5 NOVEL ONCOLYTIC IMMUNOTHERAPIES WILL BE DEVELOPED BASED ON TRANSGENE'S NEW INVIR.IO(TM) PLATFORM.TRANSGENE TO RECEIVE $10 MILLION UPON SIGNING AND IS ELIGIBLE TO RECEIVE FURTHER DEVELOPMENT MILESTONE PAYMENTS AND ROYALTIES.TRANSGENE IS TO RECEIVE ADDITIONAL PRE-CLINICAL SUCCESS MILESTONES OF UP TO $3 MILLION.  Full Article

Transgene FY Net Result Turns To Profit Of 8.0 Million Euros
Wednesday, 20 Mar 2019 

March 20 (Reuters) - TRANSGENE SA ::FY NET RESULT EUR 8.0 MILLION VERSUS LOSS OF EUR 32.3 MILLION YEAR AGO.FY OPERATING INCOME EUR 43 MILLION VERSUS EUR 8.1 MILLION YEAR AGO.CASH POSITION AT YEAR END EUR 17 MILLION VERSUS EUR 41.4 MILLION YEAR AGO.  Full Article

Transgene: Positive Results From Phase 1b Trial Of TG1050
Wednesday, 10 Oct 2018 

Oct 10 (Reuters) - TRANSGENE SA ::TRANSGENE TO PRESENT POSITIVE RESULTS FROM PHASE 1B TRIAL OF TG1050 IN PATIENTS WITH CHRONIC HEPATITIS B AT UPCOMING AASLD LIVER MEETING 2018.PHASE 1B TRIAL REACHED ITS SAFETY PRIMARY ENDPOINT.THERAPEUTIC VACCINE TG1050 BREAKS IMMUNE TOLERANCE IN PATIENTS WITH CHRONIC HEPATIS B VIRUS (HBV) INFECTION.WILL ALSO PRESENT NEW AND PROMISING PRECLINICAL DATA THAT SHOWED AN IMPROVED ANTIVIRAL ACTIVITY OF TG1050.  Full Article

Transgene H1 Operating Loss Narrows To 13.3 Million Euros
Wednesday, 19 Sep 2018 

Sept 19 (Reuters) - TRANSGENE SA ::H1 OPERATING LOSS EUR 13.3 MILLION VERSUS LOSS OF EUR 16.1 MILLION YEAR AGO.H1 COMPREHENSIVE NET LOSS EUR 14.9 MILLION VERSUS LOSS OF EUR 18.3 MILLION YEAR AGO.H1 OPERATING REVENUES EUR 3.5 MILLION VERSUS EUR 3.9 MILLION YEAR AGO.CONFIRMS FINANCIAL VISIBILITY FOR THE NEXT 12 MONTHS.AT END H1 EUR 33.0 MILLION IN CASH AND CASH EQUIVALENTS PROVIDING FINANCIAL VISIBILITY UNTIL THE END OF SEPTEMBER 2019.WE EXPECT TO ANNOUNCE MORE COMPREHENSIVE CLINICAL RESULTS FROM OUR STRATEGIC STUDIES BEFORE THE END OF 2018 AND OVER THE COURSE OF 2019 - CEO.  Full Article

Transgene Q1 Operating Revenue Stable At 1.8 Million Euros
Thursday, 26 Apr 2018 

April 26 (Reuters) - Transgene SA ::TRANSGENE: €35.6 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018.CLINICAL TRIALS NOW ON-GOING WITH 5 IMMUNO-THERAPEUTICS.CLINICAL READOUTS EXPECTED FOR EACH OF OUR 5 PRODUCTS IN 2018.Q1 OPERATING REVENUE EUR 1.8 MILLION VERSUS EUR 1.9 MILLION YEAR AGO.TRANSGENE EXPECTS ITS CASH BURN FOR 2018 TO BE COMPARABLE TO 2017.TRANSGENE CONFIRMS THAT IT EXPECTS READOUTS IN 2018 FOR EACH OF ITS 5 PRODUCTS IN CLINICAL DEVELOPMENT.  Full Article

Photo

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.